The CSL Ltd (ASX: CSL) share price is in focus after the company announced an exclusive agreement to co-develop and co-promote lixudebart for rare kidney and liver diseases, with an initial US$355 million payment to Alentis Therapeutics and plans for expanded trials.
Image source: Getty Images
What did CSL report?
- Entered exclusive deal with Alentis Therapeutics for lixudebart, a treatment targeting rare kidney and liver conditions
- CSL to make an upfront payment of US$355 million to Alentis
- Additional commercial milestone payments of up to US$1.2 billion possible
- CSL will fund all upcoming Phase 2 and 3 trials for lixudebart in key indications
- Profits from global sales to be shared, with 55% to CSL and 45% to Alentis
What else do investors need to know?
CSL's new agreement centres around lixudebart, a novel antibody designed to slow both inflammation and fibrosis—key factors in organ damage for conditions like ANCA-associated vasculitis and rapidly progressive glomerulonephritis (AAV-RPGN). Both are life-threatening and currently have limited treatment options.
The company plans to expand clinical trials to cover other rare diseases such as focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC), supporting the growth of CSL's nephrology portfolio.
What did CSL management say?
Executive Vice President and Head of R&D Dr Bill Mezzanotte said:
We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease…Our collaboration with Alentis reflects CSL's commitment to building a leading global nephrology franchise, and our strategic intent to create high-value external partnerships.
What's next for CSL?
Looking forward, CSL aims to complete the ongoing Phase 2 clinical trial for lixudebart and start new trials in additional rare kidney and liver diseases. The company's strategy is to strengthen its position in nephrology through innovation and global partnerships.
Investors can expect further updates as results from these trials are released and as CSL moves closer to potential commercialisation, which would generate shared global profits.
CSL share price snapshot
Over the past 12 months, CSL shares have declined 15%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 3% over the same period.
